Unlike studies of antibody-rich transfusions in hospitalized patients, which overall have not found clear benefits, a new randomized trial finds that early convalescent plasma treatment cuts hospitalizations in half.
Current evidence suggests the treatment does not improve survival or reduce the need for ventilation in COVID-19 patients, the World Health Organization says.